Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Sentman

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Immunotherapy|August 2, 2013
Challenges of creating effective chimeric antigen receptors for cancer therapyCharles L Sentman
Experimental Cell Research|September 21, 2005
GFP transgenic mice show dynamics of lung macrophagesMartin Grundy, Charles L Sentman
Cancer Research|February 2, 2011
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cellsTong Zhang, Charles L Sentman
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2013
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cellsTong Zhang, Charles L Sentman
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2009
Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunityAmorette Barber, Charles L Sentman
Blood|April 27, 2011
NKG2D receptor regulates human effector T-cell cytokine productionAmorette Barber, Charles L Sentman
Experimental Cell Research|September 29, 2006
Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissuesMartin A Grundy, Charles L Sentman
Cancer Journal (Sudbury, Mass.)|March 27, 2014
NKG2D CARs as cell therapy for cancerCharles L Sentman, Kenneth R Meehan
Cancer Gene Therapy|March 9, 2018
T-bet promotes potent antitumor activity of CD4<sup>+</sup> CAR T cellsAlbert T Gacerez, Charles L Sentman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell LymphomaNicole C Smits, Charles L Sentman
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Immunotherapy|August 2, 2013
Challenges of creating effective chimeric antigen receptors for cancer therapyCharles L Sentman
Experimental Cell Research|September 21, 2005
GFP transgenic mice show dynamics of lung macrophagesMartin Grundy, Charles L Sentman
Cancer Research|February 2, 2011
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cellsTong Zhang, Charles L Sentman
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2013
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cellsTong Zhang, Charles L Sentman
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2009
Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunityAmorette Barber, Charles L Sentman
Blood|April 27, 2011
NKG2D receptor regulates human effector T-cell cytokine productionAmorette Barber, Charles L Sentman
Experimental Cell Research|September 29, 2006
Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissuesMartin A Grundy, Charles L Sentman
Cancer Journal (Sudbury, Mass.)|March 27, 2014
NKG2D CARs as cell therapy for cancerCharles L Sentman, Kenneth R Meehan
Cancer Gene Therapy|March 9, 2018
T-bet promotes potent antitumor activity of CD4<sup>+</sup> CAR T cellsAlbert T Gacerez, Charles L Sentman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell LymphomaNicole C Smits, Charles L Sentman
Pageof 8